Monogram Biosciences

Monogram Biosciences, Inc. is a biotechnology laboratory based in South San Francisco, California. The company was originally established as ViroLogic Inc. in 1996 by Daniel Capon, Martin Goldstein, and Robert S. Capon. It developed laboratory assays intended to provide clinicians and pharmaceutical companies with information useful for selecting and monitoring treatments, particularly in infectious disease and oncology. The company's best-known offering is the Trofile assay, a laboratory test designed to determine the HIV-1 coreceptor tropism of a patient's virus. HIV can use different coreceptors, including CCR5 and CXCR4, when entering cells. Determining tropism became clinically relevant as CCR5-antagonist medicines were developed, because those medicines are intended for patients whose virus uses the CCR5 pathway. Monogram's testing platform was therefore positioned as a treatment-selection and companion-diagnostic tool rather than as a general screening product. Monogram's work also included assays for measuring viral characteristics and drug susceptibility. Its technology was used in HIV research and clinical care, and the company publicized studies examining the relationship between coreceptor tropism, disease progression, and responses to therapy. Reference material also describes work involving hepatitis and cancer, reflecting a broader strategy of applying molecular testing to treatment guidance across infectious diseases and oncology. The business was publicly traded on Nasdaq under the symbol VLGC after its initial public offering in 2000. In June 2009, Laboratory Corporation of America acquired Monogram Biosciences. Following the acquisition, Monogram became part of Labcorp's wider laboratory and diagnostics organization. Its corporate identity is consequently best understood as a specialized diagnostics and biotechnology brand within a larger clinical-laboratory group, rather than as an independent listed company. Monogram's historical significance rests on the development and commercialization of molecular assays that connected laboratory characterization of disease with therapeutic decisions. Its Trofile program was closely associated with the clinical development and use of CCR5-antagonist HIV therapy, including Pfizer's maraviroc, marketed as Selzentry in the United States. The available reference material does not establish a separate current consumer-facing product portfolio, independent headquarters after the Labcorp acquisition, or a standalone public-market presence.

Monogram Biosciences traces its origins to ViroLogic Inc., which was founded in 1996 by Daniel Capon, Martin Goldstein, and Robert S. Capon. The company was established as a biotechnology laboratory focused on developing tests that could characterize infectious diseases and help connect laboratory findings with treatment decisions. Its work was particularly relevant to HIV, where differences in viral biology can affect which medicines are likely to be effective. During its early development, the company built a business around molecular and phenotypic testing rather than conventional pharmaceutical products. Its assays were intended to measure clinically meaningful properties of a patient's virus, including susceptibility and coreceptor usage. This approach positioned the company at the intersection of biotechnology, clinical laboratory services, and pharmaceutical development. The tests could be used in clinical decision-making, drug-development programs, and studies evaluating treatment response. ViroLogic became a public company in 2000, trading on Nasdaq under the symbol VLGC. Public-company status provided a platform for expanding its assay development and commercialization activities. Over time, the business adopted the Monogram Biosciences name and broadened its stated areas of interest beyond HIV to include hepatitis and cancer. The company continued to emphasize diagnostic information that could guide therapy, rather than positioning its products as standalone disease treatments. The Trofile assay became the company's most prominent program. Trofile was designed to identify the coreceptor tropism of HIV-1. This distinction mattered because some HIV medicines, particularly CCR5 antagonists, work only when the patient's virus uses the CCR5 coreceptor. Monogram's test was therefore connected to the clinical development and prescribing strategy for maraviroc, Pfizer's CCR5-antagonist medicine marketed in the United States as Selzentry. The company publicized research reporting on the assay's accuracy, its clinical significance, and the relationship between HIV tropism and disease progression. It also promoted subsequent versions and additional tropism tests intended to improve patient selection. The company collaborated with pharmaceutical and research organizations in the HIV field. Its relationship with Pfizer linked the Trofile program to a major drug-development and treatment initiative, while published and publicized studies sought to establish the assay's reliability and usefulness. These activities illustrate the role of specialized diagnostics in targeted or mechanism-specific therapy: the laboratory test helped determine whether a patient's virus had the biological characteristics required for a particular treatment strategy. In June 2009, Laboratory Corporation of America acquired Monogram Biosciences. The transaction moved Monogram from independent public-company status into the Labcorp organization. After the acquisition, Monogram's identity became associated with Labcorp's broader clinical laboratory and diagnostics capabilities. The acquisition also placed the company's infectious-disease and oncology assay expertise within a larger laboratory network. The available reference material does not provide a complete account of post-acquisition management, product discontinuations, or the precise current operating structure of the Monogram name. It does establish the company's historical role in developing treatment-guidance assays, especially HIV-1 tropism testing. Monogram is consequently best characterized as a specialized biotechnology and molecular-diagnostics brand whose most visible contribution was translating HIV viral characterization into information used for therapeutic selection.

• 2009

  Acquisition by Labcorp

  [1]Monogram Biosciencesen.wikipedia.org

  Laboratory Corporation of America acquired Monogram Biosciences in June 2009.

• 2000

  Initial public listing

  [1]Monogram Biosciencesen.wikipedia.org

  ViroLogic became publicly traded on Nasdaq under the ticker VLGC.

• 1996

  ViroLogic is founded

  [1]Monogram Biosciencesen.wikipedia.org

  Daniel Capon, Martin Goldstein, and Robert S. Capon founded ViroLogic Inc., the company that later became Monogram Biosciences.

Specialized molecular diagnostics for treatment selection and disease management, with historical emphasis on HIV coreceptor tropism and other infectious-disease and oncology applications.

• HIV molecular diagnostic assay

  Trofile

  Trofile is Monogram's HIV-1 coreceptor tropism assay. It determines whether a patient's virus primarily uses the CCR5 or CXCR4 coreceptor, or a mixture of pathways. This information is relevant when considering CCR5-antagonist therapy, because the treatment requires the virus to use the CCR5 pathway. Monogram developed and promoted successive versions of the test and presented evidence concerning its accuracy, clinical significance, and role in selecting patients for maraviroc therapy.

• Infectious-disease treatment-guidance testing

  HIV viral-characterization assays

  Monogram developed laboratory assays intended to characterize HIV and provide information relevant to treatment selection and monitoring. The company's broader HIV testing work included analysis of viral properties and drug-response-related characteristics, supporting both clinical use and pharmaceutical research. The available sources do not provide a complete product list or current catalog.

• Molecular diagnostics

  Infectious-disease and oncology assays

  Monogram's stated development scope included assays for infectious diseases such as HIV and hepatitis, as well as cancer-related applications. These tests were intended to help guide or improve treatment decisions. The supplied references do not identify enough individual assay names, launch dates, or current availability to describe a more detailed portfolio without speculation.

• 2009

  Accept acquisition by LabcorpM&A

  Background

  Monogram operated as an independent public biotechnology company with specialized infectious-disease and oncology assay capabilities.

  Action taken

  Laboratory Corporation of America acquired Monogram Biosciences in June 2009.

  Aftermath

  Monogram became a Labcorp subsidiary and ceased to operate as an independent listed company.

  Source

• 2000

  Pursue public-company financing for assay developmentStrategy

  Background

  ViroLogic was developing specialized laboratory assays for HIV and other treatment-related applications and became publicly traded during its expansion.

  Action taken

  The company listed on Nasdaq under the ticker VLGC.

  Aftermath

  The listing established ViroLogic as an independent public biotechnology company before its later acquisition by Labcorp.

  Source

• Launch and refinement of the Trofile tropism assayProduct launch

  Background

  The emergence of CCR5-antagonist HIV therapy created a need to identify patients whose virus used the CCR5 coreceptor.

  Action taken

  Monogram introduced and developed Trofile testing to determine HIV-1 coreceptor tropism and support selection of patients for maraviroc therapy.

  Aftermath

  The assay became the company's signature diagnostic program and was linked to clinical research and treatment decisions involving Pfizer's Selzentry.

  Source

• 2009

  Monogram Biosciences acquired by Laboratory Corporation of America[1]Monogram Biosciencesen.wikipedia.org

  M&A

  Labcorp acquired Monogram Biosciences in June 2009, ending the company's status as an independent public company and incorporating it into Labcorp's laboratory business.

• 2000

  ViroLogic becomes a publicly traded biotechnology company[1]Monogram Biosciencesen.wikipedia.org

  Other

  The company originally known as ViroLogic became publicly listed on Nasdaq under the ticker VLGC.

• Monogram launches an updated Trofile HIV coreceptor tropism test[1]Monogram Biosciencesen.wikipedia.org

  Product launch · Product generation

  Monogram announced a new version of its Trofile assay to identify patients eligible for treatment with the CCR5 antagonist maraviroc, marketed as Selzentry by Pfizer in the United States.

• Monogram and Pfizer collaborate on HIV treatment support[1]Monogram Biosciencesen.wikipedia.org

  Other

  Monogram worked with Pfizer in connection with HIV treatment and the use of tropism testing to support selection of patients for CCR5-antagonist therapy.

1. 1Monogram Biosciencesen.wikipedia.org